232 related articles for article (PubMed ID: 30142009)
1. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
2. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
3. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
9. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of autophagy and cell viability by ceramide species.
Cruickshanks N; Roberts JL; Bareford MD; Tavallai M; Poklepovic A; Booth L; Spiegel S; Dent P
Cancer Biol Ther; 2015; 16(5):733-42. PubMed ID: 25803131
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
12. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
14. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Tang Y; Yacoub A; Hamed HA; Poklepovic A; Tye G; Grant S; Dent P
Cancer Biol Ther; 2012 May; 13(7):567-74. PubMed ID: 22406992
[TBL] [Abstract][Full Text] [Related]
16. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
[TBL] [Abstract][Full Text] [Related]
17. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Ahmed AA; Neidle S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33227941
[TBL] [Abstract][Full Text] [Related]
18. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
19. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
